GLP1R and metabolic dysfunction-associated steatotic liver disease: In view of the recent interest in GLP-1R agonism as a nonalcoholic fatty liver disease treatment, we evaluated liver histology after chronic treatment, showing greater steatosis resolution with exendin-phe1 (Fig. 9g, Supplementary Fig. 9h).